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http://dx.doi.org/10.1016/j.ccr.2013.09.010SUMMARYThe semaphorin guidance molecules and their receptors, the plexins, are often inappropriately expressed in
cancers. However, the signaling processes mediated by plexins in tumor cells are still poorly understood.
Here, we demonstrate that the Semaphorin 3E (Sema3E) regulates tumor cell survival by suppressing an
apoptotic pathway triggered by the Plexin D1 dependence receptor. In mouse models of breast cancer, a
ligand trap that sequesters Sema3E inhibited tumor growth and reduced metastasis through a selective
tumor cytocidal effect. We further showed that Plexin D1 triggers apoptosis via interaction with the orphan
nuclear receptorNR4A1.These resultsdefineacritical roleofSema3E/PlexinD1 interaction in tumor resistance
to apoptosis and suggest a therapeutic approach based on activation of a dependence receptor pathway.INTRODUCTION
Anticancer therapies targeting signaling pathways that are dis-
rupted or modulated and causally implicated in tumor progres-
sion may lead to enhanced, tumor-type-specific treatment for
cancer patients. Specifically, dysregulation of genes initially
identified as embryonic regulators of neuronal axon guidance
has been observed in many forms of cancer. The increasing
understanding of the role of neural guidance factors in the regu-
lation of various phases of cancer development offers promise
for the design of therapeutic strategies (Ballard and Hinck,
2012; Chen, 2012; Rehman and Tamagnone, 2013).
The semaphorins constitute one of the largest families of
guidance molecules, which use plexin proteins as their mainSignificance
Cell death suppression plays a central role in tumor developm
tegies developed by cancer cells to survive, one consists of p
would normally occur in settings of ligand limitation. Here, we id
that production of its ligand Sema3E promotes tumor cell surv
receptor pathway by using a Plexin D1 ligand trap is sufficient
of breast cancer. This reveals a potential therapeutic strategy
receptor interaction.
Cansignal-transducing receptors. Abnormal expression levels of
semaphorins and their receptors are commonly observed in
cancers. For example, expression of the Plexin D1 receptor
has been reported in tumor vasculature and in malignant cells
in a wide range of human cancer types (Casazza et al., 2010;
Roodink et al., 2005, 2009; Shalaby et al., 2012; Tseng et al.,
2011). Expression levels of its Sema3E ligand appear to be posi-
tively correlated with increased metastatic disease in ovarian,
melanoma, and colon cancers and with poor patient survival in
colorectal and pancreatic cancers (Biankin et al., 2012; Casazza
et al., 2010; Tseng et al., 2011).
Most of our current knowledge of the function of Sema3E/
Plexin D1 signaling in cancer was obtained from experiments
in which tumor cells were engineered to overexpress Sema3Eent, cancer progression, and treatment failure. Among stra-
reventing dependence-receptor-induced cell death, which
entify Plexin D1 as a dependence receptor and demonstrate
ival. We provide evidence that potentiating this dependence
to reduce tumor growth and metastasis in preclinical models
for breast cancer treatment based on a ligand/dependence
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Figure 1. Increased Expression of Sema3E Correlates with Metastasis in Breast Cancer
(A and B) Expression of SEMA3E and PLXND1mRNA was examined by qRT-PCR on tumor biopsies obtained from patients with tumors localized to the breast
(N0), with only axillary node involvement (N+M0), and with distant metastases (M+) (A). The average of SEMA3E and PLXND1 expression is indicated for each
tumor stage (B).
(C) Representative Sema3E and Plexin D1 immunohistochemistry on sections of two human tumors presented in (A) is shown.
Scale bar is 20 mm. See also Figure S1.
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Plexin D1 Functions as Sema3E Dependence Receptorand transplanted in animals. Two main, albeit antagonistic,
effects have been reported. First, overexpression of Sema3E,
which acts as a repulsive factor for Plexin-D1-expressing endo-
thelial cells (Gu et al., 2005), leads to decreased neoangiogene-
sis and reduced tumor growth (Casazza et al., 2010; Kigel et al.,
2008; Sabag et al., 2012; Tseng et al., 2011). On the other hand,
overexpression of a Sema3E fragment (p61-Sema3E), corre-
sponding to the 61-kDa furin cleavage product of full-length
Sema3E, contributes in an autocrine manner to cancer cell inva-
sion and formation of distant metastases (Casazza et al., 2010,
2012; Christensen et al., 2005; Tseng et al., 2011). Themolecular
mechanisms by which Sema3E/Plexin D1 signaling influences
metastatic spread are probably multiple and may depend on
the type and location of the cancer. So far, two models have
been proposed: ligand-induced activation of Plexin D1 on tumor
cells facilitates cancer cell invasive migration through complex
formation and transactivation of the epidermal growth factor
receptor 2 (ErbB2) (Casazza et al., 2010) or through regulation
of the subcellular location and activity of the Snail transcriptional
repressor during epithelial-to-mesenchymal transition (EMT)
(Tseng et al., 2011).
Breast cancer in females is the most frequently diagnosed
cancer. Despite significant advances in treatment metastatic
breast cancer remains essentially incurable, indicating a critical
need for identifying the mechanisms and genes responsible for
tumor progression. Sema3E was identified as a gene expressed
in murine mammary adenocarcinoma cell lines capable of
metastasizing to the lung and bones, but only rarely expressed
in nonmetastatic cells (Christensen et al., 1998). Sema3E
transcript was also detected in human breast cancers, yet it
is unclear whether its expression correlates with metastatic674 Cancer Cell 24, 673–685, November 11, 2013 ª2013 Elsevier Incdisease (Christensen et al., 2005). In this study, we investigated
the involvement and mechanism of action of Sema3E/Plexin D1
signaling in metastatic breast cancer, and then further applied
this information to the preclinical development ofmolecularly tar-
geted anticancer agents.
RESULTS
Increased Sema3E Level Correlates with Metastatic
Progression of Human Breast Cancers
To begin, we measured PLXND1, SEMA3E, and SEMA4A
mRNA abundance by quantitative real-time PCR in a panel of
68 primary breast tumor biopsies obtained from patients with
tumors localized to the breast (N0, 15 patients), with only axillary
lymph node involvement (N+M0, 40 patients), or with distant
metastases at diagnosis (M+, 13 patients). Plexin D1 was de-
tected in all tumor samples and average levels were relatively
constant among the different classes of tumors. In contrast,
expression of Sema3E gradually increased with progression
and was significantly higher in M+ patients compared to N0
patients, with 4/13 (30.8%) of M+ patients showing at least
a 5-fold increase in Sema3E expression levels (Figures 1A
and 1B). Immunohistochemical analysis confirmed elevated
Sema3E expression in invasive breast cancers, despite un-
changed Plexin D1 expression levels (Figure 1C; Figures S1A
and S1B available online). Finally, expression of another ligand
of the Plexin D1 receptor, Sema4A, in the breast tumors was
low and did not vary with metastatic progression (Figures S1C
and S1D). These results suggest that Sema3E/Plexin D1
signaling in human breast cancers correlates with distant meta-
static disease..
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Plexin D1 Functions as Sema3E Dependence ReceptorPlexin D1 Triggers Apoptotic Cell Death when
Dissociated from Its Semaphorin Ligands
To investigate Plexin D1 function, we transfected HEK293T cells
with plasmids encoding human or mouse Plexin D1 receptor. A
significant increase in cell death was observed, as measured
by a trypan blue exclusion assay (Figure 2A), anti-active
caspase-3 immunofluorescence (Figures 2B and 2C), and MTT
assay (data not shown). Inhibitors of caspase-3/caspase-7 and
caspase-9, but not of caspase-8, abolished Plexin-D1-induced
cell death (Figure 2D). Similar results were observed when using
small interfering RNA (siRNA) sequences against each individual
caspase (Figure 2E). Thus, expression of Plexin D1 induces
caspase-dependent apoptosis.
A potential explanation for this observed phenomenon is pro-
vided by the dependence receptor paradigm, which defines a
family of receptors active both in the presence and in the
absence of their ligands. Whereas ligand binding to dependence
receptors activates ‘‘classical’’ signaling pathways, unliganded
dependence receptors actively induce apoptosis (Gold-
schneider and Mehlen, 2010). To determine whether Plexin D1
is a dependence receptor, we first expressed in HEK293T cells
a Plexin D1 mutant (hPlxD1-RA) lacking intrinsic GTPase-
activating protein (GAP) activity, which fails to mediate
Sema3E-induced repulsion (Casazza et al., 2010; Uesugi et al.,
2009). hPlxD1-RA displayed similar cell death induction in
HEK293T cells as the wild-type receptor (Figures 2A–2C), indi-
cating that Plexin D1 triggers apoptosis independently of its
classical signaling properties as a GAP. We next tested whether
the death activity of Plexin D1 was dependent on the presence of
its ligands. Cell death induced by wild-type and mutant recep-
tors was inhibited by adding 100 ng/ml recombinant Sema3E
to the culture medium (Figure 2F). Changes in Plexin D1 expres-
sion were unlikely to account for this rescue because Plexin D1
protein levels were unaffected by Sema3E treatment (Fig-
ure S2A). We also tested the effect of Sema4A, which has
been reported to bind to Plexin D1 with an affinity 10-fold lower
than that of Sema3E (Toyofuku et al., 2007). When used at the
same concentration as Sema3E, a soluble form of Sema4A
was ineffective to save Plexin-D1-expressing HEK293T cells
from death; however, it did so when used at a concentration
10 times higher (1,000 ng/ml) (Figure 2G). Finally, a lack of rescue
was observed with semaphorins that do not bind to Plexin D1
(including Sema3A, Sema3C, and Sema3F), added at 100 ng/
ml (Figure 2G) or at higher concentrations (data not shown).
Thus, Plexin D1 is a member of the dependence receptor family
capable of triggering cell death when dissociated from its sema-
phorin ligands.
Silencing Sema3E in Breast Cancer Cells Induces
Apoptosis through the Dependence Receptor Plexin D1
To investigate whether Sema3E/Plexin D1 signaling regulates
tumor cell viability, we used the mouse mammary 4T1 tumor
cell line as a model of highly metastatic breast cancer cells
(Aslakson and Miller, 1992). In vitro, 4T1 cells express Plexin
D1 receptor and Sema3E but not Sema4A (Christensen et al.,
1998) (Figure S2B). We found that transfecting 4T1 cells with a
small hairpin RNA (shRNA) targeting Sema3E induced significant
cell death, which was reversed by cotransfection of a Sema3E
expression plasmid or by applying exogenous Sema3E proteinCan(Figures 2H, 2I, and S2C). Similar results were obtained using a
second shRNA construct (Figures S2C–S2E). One possible
explanation for increased cell death is that Sema3E activates
survival signaling mediated by Plexin D1. If that were indeed
the case, removing Plexin D1 from tumor cells should result in
a similar increase in cell death. However, treating 4T1 cells
with siRNAs targeting Plexin D1 failed to affect cell viability (Fig-
ures 2J and S2F). Another explanation is that downregulation of
Sema3E triggers cell death through unbound Plexin D1. Indeed,
we observed that cell death induced by silencing of Sema3E
expression was prevented in 4T1 cells that concomitantly
received siRNAs against Plexin D1 (Figures 2K and S2G).
To examine whether the preceding results can be extended to
other cancer cells, we knocked down Sema3E in MDA-MD-231
and MCF-7 cells, two human breast cancer cell lines that coex-
press Sema3E and Plexin D1 (Kigel et al., 2008) (Figure S2H). Cell
death induction was also observed in these conditions and was
rescued by recombinant Sema3E (Figures 2L, 2M, and S2I).
Finally, silencing Sema3E in MDA-MB-468 cells, which lack the
death-triggering Plexin D1 receptor, did not promote cell death
(Figures 2N and S2J).
Together, these observations argue that Sema3E production
by cancer cells promotes their survival by inhibiting cell death
mediated by the dependence receptor Plexin D1.
The SD1 Ligand Trap Blocks Sema3E/Plexin D1
Interaction and Induces Death of Breast Cancer Cells
In Vitro
The results described above suggest that upregulation of
Sema3E in metastatic breast cancers may protect tumor cells
against the proapoptotic activity of Plexin D1, further favoring
tumor development at primary and/or secondary sites. To
provide support for this model, we attempted to develop a
molecular compound that inhibits Plexin D1 interaction with its
ligands. We reasoned that a soluble recombinant protein con-
sisting of the Sema domain of human Plexin D1 (hereinafter
called SD1) could act as a ligand-binding trap. The interaction
between SD1 and Sema3E ligand was confirmed by in vitro
pull-down assay (Figure 3A). A weak potential interaction
between SD1 and Sema4A was not detected by coimmunopre-
cipitation (data not shown). SD1 was found to exert an inhibitory
effect on Sema3E/Plexin D1 binding with a half-maximal inhibi-
tory concentration (IC50) of 2.5 mg/ml (Figure 3B). We further
validated that SD1 triggers death of 4T1 tumor cells in a dose-
dependent manner, an effect that was reversed by adding
excess of Sema3E (Figures 3C–3E). As expected, Sema4A was
less effective than Sema3E in rescuing cells from death and
required a concentration 10-fold higher than Sema3E (Figure 3F).
These data demonstrate that a soluble compound that corre-
sponds to the Sema domain of Plexin D1 acts as a ligand trap
and triggers death of Plexin-D1-expressing cancer cells in vitro.
SD1 Inhibits Primary Tumor Growth and Metastasis
To determine whether the induction of cell death by SD1 inter-
fered with tumor development and progression in vivo, we stably
expressed in 4T1 cells a vector encoding SD1 (4T1-SD1) or a
control vector (4T1-cont), together with a myristoylated Cherry
(mCherry) encoding plasmid that allows transplanted cells
to be visualized in vivo. Western blot analysis of cell culturecer Cell 24, 673–685, November 11, 2013 ª2013 Elsevier Inc. 675
Figure 2. Unliganded Plexin D1 Receptor Induces Apoptosis in a Manner Analogous to Dependence Receptors
(A–C) HEK293T cells were transfected with an empty vector or vectors encoding human Plexin D1 (hPlxD1), mouse Plexin D1 (mPlxD1), or human Plexin D1
mutated in GAP activity domains (hPlxD1-RA). Cell death wasmeasured by trypan blue exclusion assay (A) or by immunostaining of cleaved caspase-3 (B and C).
(D and E) HEK293T cells transfected with empty vector or hPlxD1-expressing vector were cultured in the presence of Z-DEVD-FMK (inhibitor of caspase-3/
caspase-7), Z-LEHD-FMK (inhibitor of caspase-9), and Z-IETD-FMK (inhibitor of caspase-8) (D) or cotransfected with siRNAs targeting caspase-3, caspase-9,
and caspase-8 (E). Cell death was measured by trypan blue exclusion.
(F and G) HEK293T cells were transfected with empty vector or vectors encoding hPlxD1or hPlxD1-RA, and cultured in the presence of soluble Sema3E (F) or
other semaphorin ligands, Sema3A, Sema3C, Sema3F, and Sema4A (G). Cell death was measured by trypan blue exclusion assay.
(H and I) 4T1 cells were transiently transfected with a control (nontargeting) shRNA or an shRNA specific to mouse Sema3E (shSema3E) and cell death was
evaluated by trypan blue exclusion assay (H) or by active caspase-3 immunoreactivity (I). Knockdown effects were rescued by performing cotransfection with a
plasmid encoding human Sema3E (hSema3E) or by addition of exogenous Sema3E ligand.
(J and K) 4T1 cells were transfected with control siRNA or siRNA targeted against mouse Plexin D1 (PlxD1 siRNA) alone (J) or together with an shRNA targeting
Sema3E (K). Cell death was measured by trypan blue exclusion. The siRNA effect was rescued by reintroduction of siRNA-resistant hPlxD1 cDNA.
(L–N) MDA-MB-231 (L), MCF-7 (M), and MDA-MB-468 (N) cells were transiently transfected with a control shRNA or an shRNA specific to human Sema3E
(shSema3E), and cell death was evaluated by trypan blue exclusion. Cell death was rescued by cotransfection with a plasmid-encoding mouse Sema3E
(mSema3E) or by adding soluble recombinant Sema3E protein.
Data are presented asmean ± SEM. *Significantly different with p < 0.05. **Significantly different with p < 0.01. ***Significantly different with p < 0.001. Scale bar is
200 mm. See also Figure S2.
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Figure 3. SD1 Blocks Sema3E Binding to
Plexin-D1-Expressing Cells and Induces
Cell Death of Aggressive Cancer Cells
Coexpressing Sema3E and Plexin D1
(A) Detergent lysates of HEK293T cells expressing
Myc-tagged SD1 and/or hexahistidine (6xHis)-
tagged Sema3E were subjected to nickel-nitrilo-
triacetic acid (Ni-NTA)-agarose pull-down experi-
ments. The pull-down products were analyzed by
immunoblot with the indicated antibodies.
(B) Displacement curve of Sema3E binding to
Plexin-D1-expressing HEK293T cells by increas-
ing concentrations of SD1 (from 0.5–6 mg/ml) is
shown.
(C–F) Quantification of SD1-induced cell death in
4T1 cells measured by trypan blue exclusion
(C and F) or by cleaved caspase-3 immunoreac-
tivity (D and E). Cell death was rescued by adding
soluble recombinant Sema3E (C) or Sema4A (F).
Data are presented as mean ± SEM. *Significantly
different with p < 0.05. ***Significantly different
with p < 0.001. Scale bar is 160 mm.
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ure S3A). SD1 expression did not affect Plexin D1 or Sema3E
protein levels in cells kept in vitro or transplanted to form solid
tumors in mice (Figures S3B and S3C). We observed that,
72 hr after plating 4T1-SD1 cells, they began to die at a signifi-
cantly higher rate than the 4T1-cont cells, presumably as a result
of the accumulation of SD1 in the culture medium (Figure S3D).
This effect was inhibited by siRNA-mediated knockdown of
Plexin D1 expression (Figure S3E). Despite increased cell death,
cell proliferation andmigration of 4T1-SD1 cells was not different
from that of control cells (Figures S3F–S3H). Similar results were
obtained by analyzing different independent 4T1-cont (n = 2) or
4T1-SD1 (n = 2) clones (data not shown). Therefore, to produce
a healthy 4T1-SD1 line destined for in vivo grafting procedures,
the SD1-containing medium was replaced every other day by
fresh culture growth medium.
In a first series of experiments, 4T1-SD1 and 4T1-cont cell
lines were tested for their ability to form primary tumors following
injection in syngeneic Balb/c mice, either subcutaneously orCancer Cell 24, 673–685, Northotopically in the mammary fat pad.
Analysis of primary tumors collected
27 days after injection indicated that
SD1 expression caused a significant
reduction in tumor size in both subcu-
taneous (Figures 4A–4C) and orthotopic
models (not shown). Thus, blocking
ligand binding to Plexin D1 with SD1
inhibited tumor growth.
We next compared the metastatic
potential of the two cell types. A
decreased number of metastatic nodules
at the surface of the lungs was found in
animals that had received 4T1-SD1 cells
compared to controls, both after subcu-
taneous (Figure 4D) and fat pad trans-
plantation (data not shown). Reduced
metastasis formation was confirmed afterquantifying the total number of surface (Figure 4E) and internal
(Figure 4F) nodules. This reduction may either reflect an antime-
tastatic effect of SD1, or it may be secondary to limited primary
tumor growth in the same animals.
To distinguish between these possibilities, a second set of
mice was injected with 4T1-SD1 or 4T1-cont cells and sacri-
ficed when primary tumors reached an average volume of
300 mm3. Because of their slow growth, 4T1-SD1-derived
tumors were collected, in average, 14–19 days later than the
control tumors (4T1-cont/subcutaneous: 46 ± 4 days postinjec-
tion [dpi]; 4T1-SD1/subcutaneous: 60 ± 3 dpi; 4T1-cont/fat
pad: 31 ± 3 dpi; 4T1-SD1/fat pad: 50 ± 6 dpi). Comparison of
lung metastasis in animals with primary tumors of similar size
still revealed a reduced number of metastatic nodules in
animals transplanted with 4T1-SD1 cells subcutaneously (Fig-
ures 4G–4K) and in fat pad (not shown). This result indicates
that the Plexin D1 ligand trap SD1 exerts a direct inhibitory
effect on metastasis formation, independent of primary tumor
growth.ovember 11, 2013 ª2013 Elsevier Inc. 677
Figure 4. SD1 Inhibits Primary Tumor
Growth and Metastasis
(A) Representative images of primary tumors
derived from 4T1-cont or 4T1-SD1 cells in-
jected subcutaneously in syngeneic Balb/c mice,
collected at day 27 postinjection, are shown.
(B and C) Volume (B) and weight (C) of tumors
described in (A) are shown.
(D) Representative images of India-ink-stained
lungs from Balb/c mice carrying primary tumors of
4T1-SD1 or 4T1-cont cells, harvested 27 days
after subcutaneous injections, are shown. Arrows
point to metastatic nodules.
(E and F) Average number of superficial (E) or total
(F) macroscopic nodules in the lungs described in
(D) are shown.
(G) Representative images of primary tumors
derived from subcutaneously injected 4T1-cont or
4T1-SD1 cells that had reached an average vol-
ume of 300 mm3 are shown.
(H and I) Volume (H) and weight (I) of primary
tumors described in (G).
(J) Representative images of India-ink-stained
lungs from Balb/c mice carrying primary tumors of
4T1-SD1 or 4T1-cont cells when primary tumors
had reached similar size are depicted. Arrows
point to metastatic nodules.
(K) Average number of visible superficial nodules
in the lungs illustrated in (J) is shown.
n = number of injected animals. Data are pre-
sented as box plots with median, interquartile
range (IRQ), and values within ± 1.5 IRQ. *Signifi-
cantly different with p < 0.05; ***significantly
different with p < 0.001. Scale bars are 4.5 mm in
(A) and (G) and 3.8 mm in (D) and (J). See also
Figure S3.
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Inducing Tumor Cell Death
To assess the mechanism by which SD1 affects tumor devel-
opment, we analyzed a set of parameters responsible for
regulating cancer growth. We excluded that SD1 affected
density and size of blood vessels and lymphatic vessels or
proliferation of tumor cells (Figures S4A–S4F). In contrast, we
observed an 3-fold increase in tumor cell death in primary
tumors formed by 4T1-SD1 cells compared to control tumors
(Figures 5A–5F). To further test whether SD1 stimulated a death
response exclusively in SD1-expressing cells (cell autono-
mously), as opposed to exerting a paracrine effect, Balb/c
mice were coinjected subcutaneously with mCherry-labeled
4T1-SD1 cells and enhanced green fluorescent protein
(eGFP)-labeled 4T1-cont cells (1:1 ratio). Analysis of caspase
activities in the developed tumors showed that 4T1-cont cells
died as frequently as 4T1-SD1 cells, indicating a paracrine
effect of the SD1 compound (Figures 5G and 5H). Interestingly,
we noted that, unlike tumor cells, stromal cells did not show
increased death in primary tumors formed by 4T1-SD1 cells
(Figures 5E–5H). However, analysis of stromal vascular cells,
which express Plexin D1, revealed a small, but significant,
death response in the presence of SD1 (Figures S4G and
S4H). These observations indicate that, consistent with the
in vitro findings, SD1 induces death of Plexin-D1-expressing678 Cancer Cell 24, 673–685, November 11, 2013 ª2013 Elsevier Inccells in vivo, and this activity may explain the decrease
observed in primary tumor growth.
To metastasize to the lung, 4T1 tumor cells must disseminate
from the primary tumor, invade the stroma to reach blood or
lymph vessels, and then extravasate and home to other tissues.
Sema3E/Plexin D1 signaling has been reported to induce
EMT and cell migration in a way that can contribute to the met-
astatic potential of a tumor (Casazza et al., 2010; Tseng et al.,
2011). However, 4T1-SD1 cells did not differ from control
cells in their expression of canonical EMT markers, cellular
morphology, or migratory properties (Figure S4I; see also Fig-
ures S3G and S3H). Increased apoptosis, on the other hand,
may explain the SD1 antimetastatic effect. One possibility is
that SD1 triggers apoptosis of circulating tumor cells as they
travel to distant sites as single cells or small clusters. The exis-
tence of an autocrine loop for tumor cell survival was demon-
strated in low-density cultures (350 cells/cm2), where isolated
4T1 cells showed increased cell death after addition of recom-
binant SD1 to the culture medium (Figure S4J). However, iso-
lated 4T1-SD1 cells cultured at the same density did not
show increased cell death as compared to 4T1-cont cells,
although they did so in high-density cultures (50,000 cells/cm2;
Figure S4K). The most likely explanation is that, in low-density
cultures, cell-produced SD1 was too dilute to exert its effect
on responding cells. It is therefore unlikely that the in vivo.
Figure 5. SD1 Induces Tumor Cell Death In Vivo
(A–D) Immunolabeling of cleaved caspase-3 and cleaved caspase-9 onwhole tumors (A andC) and sections of primary tumors (B and D) derived from 4T1-cont or
4T1-SD1 cells injected subcutaneously into syngeneic Balb/c mice, collected 27 days postinjection, is shown. Inset panels in (B) and (D) show overlap of caspase
and mCherry staining in individual 4T1 cells.
(E and F) Quantification of cleaved caspase-3 and cleaved caspase-9 immunostaining on tissue sections of primary tumors illustrated in (B) and (D) is
shown.
(G andH) Quantification of cleaved caspase-3 and cleaved caspase-9 positive stromal and tumor cells on sections of primary tumors obtained from coinjection of
mCherry-labeled 4T1-SD1 cells and eGFP-labeled 4T1-cont cells (ratio 1:1) subcutaneously into syngeneic Balb/c mice, collected 27 days postinjection, is
shown.
(I) Sections of lungs bearing 4T1-cont or 4T1-SD1 metastases (dotted line) were immunostained for active caspase-3 and revelation was performed using the
peroxidase substrate DAB (brown color).
(J) Quantification of metastatic nodule surface area on sections of lungs bearing metastases of 4T1-cont or 4T1-SD1 cells is shown.
Data are presented as mean ± SEM (E–H) or as box plots with median, interquartile range (IRQ), and values within ± 1.5 IRQ (J). *Significantly different with
p < 0.05; ***significantly different with p < 0.001. Scale bars are 3.5 mm in (A) and (C), 50 mm in (B) and (D), 20 mm in inset panels in (B) and (D), and 500 mm in (I).
See also Figure S4.
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cells. Alternatively, SD1 expression may induce tumor cell
death during the growth of disseminated tumor cells into
macroscopic tumor nodules. In support of this idea, increase
in activated caspase-3 immunostaining was evident in the
pulmonary metastases of animals injected with 4T1-SD1 cellsCancompared to controls (Figure 5I). Consistent with increased
apoptosis, the metastatic nodules that formed in the 4T1-
SD1-administered groups were smaller in size than those of
control animals (Figure 5J). Thus, the antimetastatic effect of
SD1 in vivo may be mediated by induction of tumor cell
apoptosis in metastatic colonies.cer Cell 24, 673–685, November 11, 2013 ª2013 Elsevier Inc. 679
Figure 6. The Inhibitory Effect of SD1 on
Tumor Growth and Metastasis Requires
Plexin D1 on Tumor Cells
(A) Representative images of primary tumors and
India-ink-stained lungs of Balb/c mice injected
subcutaneously with 4T1-cont or 4T1-SD1 cells
transfected with a control shRNA (shCont) or an
shRNA to Plexin D1 (shPlxD1), collected 27 days
postinjection, are shown. The arrows point to the
metastatic nodules in the lungs.
(B and C) Volume (B) and weight (C) of primary
tumors described in (A) are shown.
(D) Average number of superficial metastatic
nodules in the lungs illustrated in (A) is shown.
(E–H) Immunolabeling of cleaved caspase-3 and
cleaved caspase-9 onwhole tumors (upper panels
in E and G) and sections from primary tumors
(lower panels in E and G) described in (A) are
shown. 4T1 cells are visualized by mCherry
expression. Inset panels in (E) and (G) show
coexpression of caspase and mCherry in individ-
ual 4T1 cells. Quantification of active caspase-3-
and active caspase-9-positive tumor cells is
shown in (F) and (H), respectively.
n = number of injected animals. Data are pre-
sented as mean ± SEM in (F) and (H) and as box
plots with median, interquartile range (IRQ), and
values within ± 1.5 IRQ in (B)–(D). **Significantly
different with p < 0.01; ***significantly different with
p < 0.001. Scale bars are 4.5 mm (A), 3.5 mm
(upper panels in E and G), 100 mm (lower panels in
E and G), and 20 mm (inset panels in E and G). See
also Figure S5.
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We next asked whether the in vivo anticancer and prodeath
effects of SD1 involved Plexin D1 dependence receptor sig-
naling. To this end, the two cell lines, 4T1-SD1 and 4T1-cont,
were stably transfected with an shRNA plasmid targeting Plexin
D1 or with a control nontarget shRNA plasmid (Figures S5A–
S5D). The obtained clones exhibited unchanged SD1 and
Sema3E expression levels (Figures S5B, S5C, and S5E).
In vitro, Plexin D1 knockdown did not affect the proliferation or
migration of tumor cells (Figures S5F–S5H). However, it rescued
by up to 70% the death of SD1-expressing 4T1 cells that other-
wise occurred after 72 hr in culture (Figure S5I). In vivo, we inves-
tigated the growth and metastatic behavior of the four different680 Cancer Cell 24, 673–685, November 11, 2013 ª2013 Elsevier Inc.cell lines (called 4T1-cont/shCont, 4T1-
cont/shPlxD1, 4T1-SD1/shCont, and
4T1-SD1/shPlxD1) in syngeneic mice
injected subcutaneously. Plexin-D1-
deficient 4T1 cells (4T1-cont/shPlxD1)
formed primary tumors that reached an
average size comparable to that of
tumors that developed from control cells
(4T1-cont/shCont) and formed a similar
number of pulmonary metastases (Fig-
ures 6A–6D). This lack of effect of Plexin
D1 knockdown was surprising, given the
previously reported role of autocrine
Sema3E signaling in inducing metastaticbehavior in cancer cells through activation of a Plexin D1–
ErbB2 receptor complex (Casazza et al., 2010). However,
analysis of ErbB2 gene expression by RT-PCR failed to detect
significant levels of ErbB2 mRNA in the parental or clonally
derived 4T1 cell lines used in the present study (Figure S5J)
(Kaur et al., 2012). Thus, in the present model, ligand-induced
classical Plexin D1 signaling appears dispensable for tumor
development and dissemination.
In contrast, in conditions where tumor growth and metastasis
were inhibited by SD1, Plexin D1 knockdown restored the ability
of 4T1-SD1 cells to form large primary tumors and to dissemi-
nate to the lungs (Figures 6A–6D). The rescue effect was accom-
panied by a significant decrease of cleaved caspase-3 and
Cancer Cell
Plexin D1 Functions as Sema3E Dependence Receptorcaspase-9 immunostaining in tumors of 4T1-SD1/shPlxD1 cells
compared to 4T1-SD1/shCont tumors (Figures 6E–6H). To
exclude the possibility of nonspecific effects, we confirmed
these results using a second shRNA sequence (Figures S5K–
S5M). Together, these data indicate that the inhibitory effect of
SD1 on cancer progression involves engagement of prodeath
signaling from the Plexin D1 dependence receptor expressed
in tumor cells.
Plexin D1 Triggers Apoptosis via an NR4A1-Dependent
Mechanism
We next attempted to determine the molecular mechanism by
which Plexin D1 induces apoptosis. First, we expressed a Plexin
D1 receptor deleted of its cytoplasmic domain (hPlxD1-DC) in
HEK293T cells. This mutant receptor lacked cell-killing activity
(Figure 7A). Conversely, the soluble cytoplasmic domain of
Plexin D1 (hPlxD1-ICD) was sufficient to achieve functional
death signaling (Figure 7A). To identify proapoptotic compo-
nents that may interact with Plexin D1 intracellular domain,
we screened a human embryonic brain cDNA library using
hPlxD1-ICD as bait in a yeast two-hybrid assay. This screen
identified the orphan nuclear receptor NR4A1, also known as
Nur77, as a potential interactor of Plexin D1 (data not shown).
Expression of NR4A1 has been reported in multiple cancer cell
lines and in patients with different types of tumor, including
breast cancer patients (Alexopoulou et al., 2010). NR4A1 exerts
a dualistic function in cancer, where it can promote tumor by
favoring cell growth and survival but can also exert tumor sup-
pression activity via a proapoptotic effect (Lee et al., 2011;
Mohan et al., 2012; To et al., 2012). The interaction between
NR4A1 and Plexin D1 was confirmed by pull-down assay in
lysates of HEK293T cells coexpressing both proteins (Figure 7B).
Interestingly, when cells were grown in the presence of Sema3E,
this interaction was abolished (Figure 7B), thus making NR4A1 a
good candidate for a role in signaling by unliganded Plexin D1
receptor.
To evaluate the functional role of the Plexin D1-NR4A1 interac-
tion, Plexin-D1-dependent cell death was measured in 4T1 cells
treated with SD1 after NR4A1 gene silencing with two indepen-
dent siRNAs. Downregulation of NR4A1 did not affect the
viability of 4T1 cells in control conditions, but it blocked the
cell death response to SD1 (Figures 7C and S6A), indicating
that NR4A1 acts downstream of unliganded Plexin D1. NR4A1
can act as a nuclear transcription factor and induce transcription
of proapoptotic genes or can translocate from the nucleus to
the cytoplasm to promote death through the mitochondrial
apoptosis pathway (Moll et al., 2006). Here, the second mecha-
nism is more likely because we observed a predominantly cyto-
plasmic distribution of NR4A1 both in 4T1 cells in vitro and in 4T1
experimental tumors (Figures 7D and 7E), as has been reported
in human breast tumors (Alexopoulou et al., 2010). Consistent
with a cytoplasmic role of NR4A1 in Plexin-D1-induced cell
death, blockade of nuclear export abolished the cell death
response induced by SD1 on 4T1 cells (Figure 7F). Moreover,
the death effect induced by SD1 still occurred in the presence
of transcription inhibitor, indicating that the death pathway
does not require transcriptional activity (Figure 7F). In addition,
in 4T1 cells transfected with NR4A1 siRNAs, expression of a
nuclear-export-deficient NR4A1 mutant failed to rescue the pro-Canapoptotic effect of SD1 as the wild-type NR4A1 did (Figures 7C
and S6). Thus, Plexin-D1-mediated cell death requires the extra-
nuclear pathway of NR4A1 action. We therefore tested whether
the mitochondrial pathway of apoptosis is activated in 4T1 cells
treated with SD1. Disruption of mitochondrial membrane integ-
rity was observed in the SD1-treated cells (Figures 7G and 7H).
Moreover, we found that SD1 treatment triggered the release
of cytochrome c to the cytoplasm, and its blockade with the
BAX channel blocker iMAC2 suppressed the death effect of
SD1 on 4T1 cells (Figures 7I and 7J). Together, these results sup-
port a model in which the unliganded Plexin D1 receptor inter-
acts with cytoplasmic NR4A1, which acts on the mitochondria
to induce cytochrome c release and subsequent activation of
the caspase cascade.
Early Preclinical Evaluation of Plexin D1 Ligand Trap in
Models of Breast Cancer
Because the SD1 trap appears to exert a tumor-growth- and
metastasis-inhibiting effect, we developed a biologic interfering
with Plexin D1/ligands interaction(s) that may be compatible
with preclinical and clinical development. Similar to the Trap-
VEGF currently in phase II clinical trials (Gaya and Tse, 2012),
we generated various SD1 variants fused to human IgG1 Fc.
These variants were then assessed in in vitro assays and through
systemic delivery in mouse models. A variant named SD1-v2,
which comprises in addition to the Sema domain the two adja-
cent cysteine-rich Plexin, Semaphorin, Integrin (PSI) domains
of Plexin D1, was analyzed further and successfully produced
in a large-scale format. SD1-v2 showed the same death effect
as SD1 onmurine and humanbreast tumor cell lines (Figure S7A).
In a first series of experiments, 4T1 cells were injected subcuta-
neously into nude mice, and the tumors were allowed to develop
until they reached a volume of 100 mm3. At this time, mice
received intraperitoneal injections of SD1-v2 or PBS, five times
a week for 2 weeks. The SD1-v2 injections slowed the growth
of primary tumors (Figure 8A). In addition, SD1-v2-treated ani-
mals had significantly fewer metastases in the lung as compared
to vehicle controls (Figure 8B). We conducted similar experi-
ments with human MDA-MB-231 breast cancer cells, which,
like 4T1 cells, formed smaller tumors when transduced to ex-
press SD1 stably (Figures S7B–S7M). SD1-v2 treatment of
nude mice bearing orthotopically implanted human MDA-MB-
231 cells significantly delayed primary tumor growth (Figure 8C).
The effect of SD1-v2 on secondary tumors was not evaluated
because of the very low incidence of lung macrometastases
observed in mice bearing MDA-MB-231 primary tumors (Rose
et al., 1994). Together, these data show that targeting endoge-
nous Plexin D1 ligands can achieve inhibition of established
primary tumors and metastases in preclinical models of breast
cancer.
DISCUSSION
The Dependence Receptor Plexin D1 Activates the
NR4A1-Mediated Mitochondrial Apoptotic Pathway
Among the nine vertebrate plexins, Plexin D1 is the most struc-
turally divergent family member (Tamagnone et al., 1999) and
so far the only one to be characterized as a dependence recep-
tor. Examples of dependence receptors include other surfacecer Cell 24, 673–685, November 11, 2013 ª2013 Elsevier Inc. 681
Figure 7. Unliganded Plexin D1 Interacts
with the NR4A1 Orphan Receptor to Induce
Activation of the Mitochondrial Pathway of
Apoptosis
(A) HEK293T cells were transfected with an empty
vector or vectors encoding human Plexin D1
(hPlxD1), hPlexin D1 deleted from its cytoplasmic
domain (hPlxD1-6C), or a soluble form of hPlexin
D1 cytoplasmic domain (hPlxD1-ICD). Cell death
was measured by trypan blue exclusion assay.
(B) HEK293T cells were transfected with expres-
sion vectors encoding VSV-tagged Plexin D1 and/
or hexahistidine (6xHis)-tagged NR4A1, treated or
not with exogenous Sema3E ligand (100 ng/ml).
Detergent cell lysates were subjected to Ni-NTA-
agarose pull-down experiments. The pull-down
products were analyzed by immunoblot with the
indicated antibodies.
(C) 4T1 cells were transfectedwith a control siRNA
or a siRNA specific to mouse NR4A1 (NR4A1
siRNA), together with an empty vector or vectors
encoding human NR4A1 (hNR4A1 AA1–598) or a
nuclear export deficient mutant of hNR4A1
(hNR4A1 AA248–580) and treated or not with SD1.
Cell death was evaluated by trypan blue exclusion
assay.
(D) Immunolabeling for NR4A1 on sections of pri-
mary tumors obtained by subcutaneous injection
of Balb/c mice with 4T1-cont or 4T1-SD1 cells is
shown.
(E) Analysis of nuclear-cytoplasmic distribution of
NR4A1 by immunofluorescence on cultured 4T1-
cont and 4T1-SD1 cells is shown.
(F) 4T1 cells were treated or not with SD1 in the
presence of Leptomycin B (1 mM; LepB) or
a-amanitin (2.5 mM; a-ama). Cell death was
measured by trypan blue exclusion assay.
(G and H) Labeling of 4T1 cells with MitoCapture
following exposure or not to SD1 (10 mg/ml) is
shown. In healthy cells, MitoCapture reagent
aggregates in the mitochondria (punctate red
fluorescence). In cells with disrupted mitochon-
drial transmembrane potential, mitochondrial
aggregate formation is prevented and Mito-
capture remains in the cytoplasm in its monomer
form (diffuse green fluorescence) (G). Quantifica-
tion of the percentages of mitochondria-disrupted
cells in each condition is shown (H).
(I) Immunolabeling for cytochrome c in 4T1 cells
treated or not with SD1 (10 mg/ml) is shown.
(J) Quantification of SD1-induced cell death in 4T1
cellsby trypanblueexclusion in thepresenceof the
Bax Channel Blocker II, iMAC2 (5 mM), is shown.
Data are presented as mean ± SEM. *Significantly
different with p < 0.05; **significantly different with
p < 0.01; ***significantly different with p < 0.001.
Scale bars are 50 mm in (D) and 30 mm in (G)
and (I). See also Figure S6.
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Plexin D1 Functions as Sema3E Dependence Receptorreceptors initially described in the context of axon guidance
(DCC, UNC5H, Neogenin, and EphA4), as well as receptors for
trophic factors (RET, IR, IGF1r, MET, ALK, TrkA, and TrkC) and
morphogens (Patched) (Goldschneider and Mehlen, 2010). The
mechanisms by which dependence receptors exert their cell-
killing effects are diverse and, in most cases, still incompletely
understood. One of the best-studied cases of dependence re-682 Cancer Cell 24, 673–685, November 11, 2013 ª2013 Elsevier Incceptor death signaling concerns Patched, which directly recruits
an atypical caspase-activating complex, the ‘‘dependosome,’’
that includes the cytoplasmic adaptor protein DRAL, TUCAN,
and caspase-9 (Fombonne et al., 2012; Mille et al., 2009). The
present data show that Plexin D1 engages an alternative mech-
anism for activation of caspase-9 via the mitochondrial death
pathway. In the absence of ligand, Plexin D1 interacts with.
Figure 8. Inhibition of Established Tumor
Growth andMetastasis Formation by In Vivo
Injection of Plexin D1 Ligand Trap
(A and B) 4T1 cells were engrafted subcutaneously
in CD-1 nude (nu/nu) athymic mice and the volume
of the tumors wasmeasured during treatment with
either PBS (control) or SD1-v2. Mean tumor vol-
ume is indicated (A). The lungs of engrafted mice
were dissected at the end of the treatment
period and the number of metastatic nodules was
assessed through visual inspection (B).
(C) MDA-MB-231 cells were injected into the
mammary fat pad of CD-1 nude (nu/nu) athymic
mice and the volume of the tumors was measured
during treatment with either PBS or SD1-v2.
n = number of animals injected. Data are pre-
sented as mean ± SEM in (A) and (C) and as box
plots with median, interquartile range (IRQ), and
values within ± 1.5 IRQ in (B). **Significantly
different with p < 0.01; ***significantly different with
p < 0.001. See also Figure S7.
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Plexin D1 Functions as Sema3E Dependence Receptorcytoplasmic NR4A1, which triggers mitochondrial apoptosis
through release of cytochrome c, an activator of the caspase-9
apoptosome. In the presence of Sema3E ligand, Plexin D1–
NR4A1 interaction is disrupted, possibly as a result of changes
in receptor structure, oligomeric state, and/or concurrent bind-
ing of the Rho GTPase Rnd2 (Janssen et al., 2010; Siebold and
Jones, 2013; Uesugi et al., 2009).
How NR4A1 induces the mitochondrial apoptosis pathway is
incompletely defined. The best-defined mechanism involves
translocation of NR4A1 to the outer mitochondrial membrane,
where it binds to the apoptosis regulator B cell lymphoma 2
(Bcl-2) (Li et al., 2000). NR4A1 binding induces a conformational
change in Bcl-2 that exposes its previously hidden BH3 domain,
resulting in conversion of Bcl-2 from an antiapoptotic to a proap-
optotic molecule (Lin et al., 2004). In this case, the initiation of
apoptosis may require proteolytic processing of Plexin D1 intra-
cellular domain, as shown for many other dependence receptors
(Goldschneider and Mehlen, 2010), to allow translocation of an
active Plexin D1–NR4A1 complex to the mitochondria. However,
direct mitochondrial targeting of cytoplasmic NR4A1 is not
always required for cell death because it has been suggested
that NR4A1 can stimulate other cytosolic proapoptotic mole-
cules, such as BAX, to associate with the mitochondria (Wilson
et al., 2003). Future studies will continue to define the mecha-
nism of action of cytoplasmic NR4A1 and how its proapoptotic
function is regulated by Plexin D1.
Disruption of Semaphorin/Plexin D1 Signaling Prevents
Breast Cancer Growth and Metastasis
The dependence receptor model predicts that such receptors
act as conditional tumor suppressors by triggering apoptosisCancer Cell 24, 673–685, Nof cancer cells in settings of ligand
limitation. Aggressive/metastatic cancers
may have evolved several strategies to
escape dependence-receptor-mediated
cell death by downregulation, or muta-
tion, of the receptor and/or downregula-
tion of its downstream effector molecules(Castets et al., 2012; Coissieux et al., 2011; Genevois et al.,
2013). Interestingly, recent analyses revealed a negative associ-
ation betweenNR4A1 expression levels in breast cancer and his-
tologic grade, with reduced expression of NR4A1 in higher grade
and metastatic tumors (Alexopoulou et al., 2010; Muscat et al.,
2013). This reduction may potentially contribute to the survival
of aggressive tumors. Alternatively, cancer cells may inhibit the
dependence-receptor-mediated cell death pathway by auto-
crine production of the trophic ligand (Bouzas-Rodriguez et al.,
2010; Fitamant et al., 2008). Consistent with this second model,
we showed here that expression of the high-affinity ligand for
Plexin D1, Sema3E, increases with tumor progression in human
breast cancers. Thus, production of the antiapoptotic ligand
Sema3E may represent a cell death evasion mechanism that
has implications in tumor growth and progression.
The results of the present study differ from those of previous
research using gene knockdown of Sema3E, which failed to
identify a role of this semaphorin in cancer cell survival and tumor
growth (Casazza et al., 2010). We have repeated these experi-
ments using 4T1 clones stably expressing Sema3E shRNAs
and confirmed that the tumors grew normally (data not shown).
Two different, but not exclusive, hypotheses may be advanced
to reconcile the apparent inconsistency between results based
on Sema3E knockdown and Plexin D1 ligand sequestration by
SD1. First, knocking down Sema3E ligand expression in 4T1
cells had a deleterious effect on cell survival, thus severely
reducing the colony number during the process of stable clone
selection. Moreover, the few recovered clones did not manifest
increased rate of cell death when expanded in vitro (unlike tran-
siently transfected 4T1 cells), indicating that Sema3E-negative
clones that have survived the selection process were resistantovember 11, 2013 ª2013 Elsevier Inc. 683
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This selection bias was circumvented during the generation of
stable clones expressing the SD1 ligand trap by selecting and
expanding the cell lines under nonapoptotic conditions (i.e., by
washing out the SD1-containing medium regularly). A second
possibility is that in vivo Sema3E-deficient 4T1 cells were saved
from Plexin-D1-induced cell death by another ligand expressed
in the tumors. Interestingly, we observed that Sema4A, which is
not expressed by 4T1 cells in vitro, is present in 4T1-derived
tumors. Taken together, these results raise the possibility that
autocrine Sema3E ligand might cooperate with Sema4A ex-
pressed in growing tumors to protect cancer cells against the
proapoptotic activity of Plexin D1.
Targeting the Plexin D1 Dependence Receptor as a
Potential Therapeutic Strategy for Breast Cancer
Although Sema3E is a potent inhibitor of tumor neoangiogenesis,
the use of recombinant Sema3E for cancer therapy is compro-
mised by its adverse prometastatic effect (Casazza et al.,
2010). Interestingly, it has been reported that a furin-resistant
form of Sema3E can inhibit metastasis while retaining its antian-
giogenic and antitumor activity (Casazza et al., 2012). This anti-
metastatic property can be explained by failure of the mutated
ligand to enhance ErbB2 recruitment to Plexin D1 and its subse-
quent transactivation (Casazza et al., 2012). The present findings
open additional possibilities for the rational design of selective
anticancer drugs that induce tumor cell death both in primary
and secondary tumors by targeting the Sema3E/Plexin D1
pathway. This approach may be valuable for the treatment of
metastatic breast cancers, including ErbB2-negative cancers.
Another antiapoptotic ligand that inhibits dependence recep-
tor function in breast tumors is Netrin-1 (Fitamant et al., 2008).
Although both Netrin-1 and Sema3E are upregulated in human
breast cancers with metastatic propensity, they are often found
overexpressed in distinct sets of tumors (data not shown). The
mechanisms leading to aberrant expression of Sema3E or
Netrin-1 in cancer are presently unclear. This understanding
might be important in the future to link patients’ tumor types to
the effectiveness of treatments targeting distinct dependence
receptor pathways and to the development of personalized anti-
cancer medicine.
EXPERIMENTAL PROCEDURES
Amore detailed description of the experimental procedures and reagents used
in this study can be found in the Supplemental Experimental Procedures.
Quantitative RT-PCR and Immunohistology on Human Breast Tumor
Samples
Human tissue samples were obtained from the Biological Resource Center
(Centre Le´on Be´rard, Agreement number: DC-2008-99), after approval by
the institutional review board and ethics committee of Centre Le´on Be´rard,
with fully informed patient consent. To assay PLXND1, SEMA3E, and SEMA4A
expression in breast tumors, total RNA was isolated and reverse-transcribed
using the iScript cDNA Synthesis kit (BioRad). The hydroxymethylbilane syn-
thase (HMBS) housekeeping gene was used as internal control. Real-time
quantitative RT-PCR was performed on a LightCycler 480 apparatus (Roche)
using the LightCycler TaqMan Master kit (Roche) and probes 42, 25, 5, and
26, respectively (Universal ProbeLibrary; Roche). Average gene expression
is given as the ratio between expression in each sample and the average of
expression in the N0 samples. Immunohistological analysis was performed684 Cancer Cell 24, 673–685, November 11, 2013 ª2013 Elsevier Incas described (Bernet et al., 2007). The pathologist selected representative
areas from breast carcinomas.
Animal Models and In Vivo Procedures
All animal procedureswere carried out in accordancewith accepted standards
of animal care, under the agreement number E-10-055-21 for animal experi-
mentation delivered by the French Ministry of Agriculture. In vivo studies
were conducted in 6- to 8-week-old female BALB/c ByJ mice or CD-1 nude
(nu/nu) athymic mice (Charles River Laboratories). Mice were injected with
4.53 105 4T1 or 23 106MDA-MB-231 cells subcutaneously into the right pos-
terior flank or into the fad pad of the mammary gland. When tumors reached a
volume of 100 mm3, PBS or 20 mg/kg of body weight SD1-v2 were adminis-
trated intraperitoneally five times per week for 2 weeks. Tumor size was
measured externally using a caliper, and the width (A) and length (B) of the
developing tumor was converted to volume using the equation V = 0.52 3
A2 3 B. The primary tumors and the lungs of the animals were dissected
and processed as described (Casazza et al., 2010).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.ccr.2013.09.010.
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